Recent partnership aims to design, develop and commercialize a companion diagnostic assay for early-stage heart failure compound.
In a recent collaboration, Siemens Healthcare Diagnostics has announced that it will be developing and commercializing a companion diagnostic test for an early-stage heart failure compound being developed by Janssen Pharmaceutica NV. The compound has been developed to target autoantibodies directed against the human β1-andrenergic receptor (β1-AR).
The immunoassay-based companion diagnostic tests to be designed by the Siemens Clinical Laboratory will be used in Janssen’s clinical studies. Also under the agreement, Siemens will develop an in vitro companion diagnostic test that can be commercialized on Siemens’ central laboratory automated immunoassay systems.
Michael Reitermann, Chief Executive Officer of Siemens Healthcare Diagnostics commented on the collaboration, “Our relationship with Janssen marks an important next step in Siemens’ personalized medicine strategy. As a leading clinical diagnostics company, with the tools and technologies to help define the future of patient care, we are looking forward to collaborating with Janssen and extending their position in cardiac therapies.”